Zydus Lifesciences will be in focus on Wednesday after receiving final USFDA approval for its Verapamil Hydrochloride Extended-Release Tablets in 120 mg, 180 mg, and 240 mg strengths. The drug, a generic version of Calan SR, is used to treat high blood pressure. The approval strengthens Zydus’ US portfolio and supports its ongoing expansion in the regulated markets.